This HTML5 document contains 103 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n19http://linked.opendata.cz/resource/drugbank/drug/DB05245/identifier/chebi/
n2http://linked.opendata.cz/resource/drugbank/drug/
dctermshttp://purl.org/dc/terms/
n11http://linked.opendata.cz/resource/drugbank/company/
n21http://linked.opendata.cz/resource/drugbank/drug/DB05245/identifier/wikipedia/
n27http://linked.opendata.cz/resource/mesh/concept/
foafhttp://xmlns.com/foaf/0.1/
n20http://linked.opendata.cz/resource/drugbank/drug/DB05245/identifier/pharmgkb/
n15http://linked.opendata.cz/resource/drugbank/dosage/
n25http://linked.opendata.cz/resource/drugbank/drug/DB05245/identifier/pubchem-compound/
n5http://bio2rdf.org/drugbank:
n28http://linked.opendata.cz/resource/drugbank/drug/DB05245/identifier/pubchem-substance/
admshttp://www.w3.org/ns/adms#
n24http://linked.opendata.cz/resource/drugbank/drug/DB05245/identifier/kegg-drug/
n18http://linked.opendata.cz/resource/drugbank/drug/DB05245/identifier/drugbank/
n9http://www.rxlist.com/cgi/generic/
n10http://wifo5-03.informatik.uni-mannheim.de/drugbank/resource/drugs/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n23http://linked.opendata.cz/resource/drugbank/drug/DB05245/identifier/national-drug-code-directory/
n22http://linked.opendata.cz/resource/drugbank/medicinal-product/
owlhttp://www.w3.org/2002/07/owl#
n26http://linked.opendata.cz/ontology/mesh/
n3http://linked.opendata.cz/ontology/drugbank/
n7http://www.drugs.com/cdi/
n8http://linked.opendata.cz/resource/drugbank/property/
xsdhhttp://www.w3.org/2001/XMLSchema#
n17http://linked.opendata.cz/resource/drugbank/drug/DB05245/identifier/chemspider/
n13http://linked.opendata.cz/resource/atc/
n12http://linked.opendata.cz/ontology/sukl/drug/

Statements

Subject Item
n2:DB05245
rdf:type
n3:Drug
n3:description
Silver sulfadiazine is a sulfa derivative topical antibacterial used primarily on second- and third-degree burns. [Wikipedia]
n3:dosage
n15:271B3EA9-363D-11E5-9242-09173F13E4C5 n15:271B3EAA-363D-11E5-9242-09173F13E4C5
n3:generalReferences
# Fox CL Jr, Modak SM: Mechanism of silver sulfadiazine action on burn wound infections. Antimicrob Agents Chemother. 1974 Jun;5(6):582-8. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/15825409 # Russell AD, Hugo WB: Antimicrobial activity and action of silver. Prog Med Chem. 1994;31:351-70. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/8029478 # Percival SL, Bowler PG, Russell D: Bacterial resistance to silver in wound care. J Hosp Infect. 2005 May;60(1):1-7. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/15823649
n3:group
approved
n3:indication
Indicated as an adjunct for the prevention and treatment of wound sepsis in patients with second- and third-degree burns.
owl:sameAs
n5:DB05245 n10:DB05245
dcterms:title
Silver sulfadiazine
adms:identifier
n17:390017 n18:DB05245 n19:9142 n20:PA164744951 n21:Silver_sulfadiazine n23:68387-450-01 n24:D00433 n25:441244 n28:46507881
n3:mechanismOfAction
Studies utilizing radioactive micronized silver sulfadiazine, electron microscopy, and biochemical techniques have revealed that the mechanism of action of silver sulfadiazine on bacteria differs from silver nitrate and sodium sulfadiazine. Silver sulfadiazine acts only on the cell membrane and cell wall to produce its bactericidal effect. A specific mechanism of action has not been determined, but silver sulfadiazine's effectiveness may possibly be from a synergistic interaction, or the action of each component. Silver is a biocide, which binds to a broad range of targets. Silver ions bind to nucleophilic amino acids, as well as sulfhydryl, amino, imidazole, phosphate, and carboxyl groups in proteins, causing protein denaturation and enzyme inhibition. Silver binds to surface membranes and proteins, causing proton leaks in the membrane, leading to cell death. Sulfadiazine is a competitive inhibitor of bacterial para-aminobenzoic acid (PABA), a substrate of the enzyme dihydropteroate synthetase. The inhibited reaction is necessary in these organisms for the synthesis of folic acid.
n3:packager
n11:271B3E92-363D-11E5-9242-09173F13E4C5 n11:271B3E90-363D-11E5-9242-09173F13E4C5 n11:271B3E91-363D-11E5-9242-09173F13E4C5 n11:271B3E8E-363D-11E5-9242-09173F13E4C5 n11:271B3E8F-363D-11E5-9242-09173F13E4C5 n11:271B3E8C-363D-11E5-9242-09173F13E4C5 n11:271B3E8D-363D-11E5-9242-09173F13E4C5 n11:271B3E8A-363D-11E5-9242-09173F13E4C5 n11:271B3E8B-363D-11E5-9242-09173F13E4C5 n11:271B3E88-363D-11E5-9242-09173F13E4C5 n11:271B3E89-363D-11E5-9242-09173F13E4C5 n11:271B3E86-363D-11E5-9242-09173F13E4C5 n11:271B3E87-363D-11E5-9242-09173F13E4C5 n11:271B3E85-363D-11E5-9242-09173F13E4C5 n11:271B3E9B-363D-11E5-9242-09173F13E4C5 n11:271B3E99-363D-11E5-9242-09173F13E4C5 n11:271B3E9A-363D-11E5-9242-09173F13E4C5 n11:271B3E97-363D-11E5-9242-09173F13E4C5 n11:271B3E98-363D-11E5-9242-09173F13E4C5 n11:271B3E95-363D-11E5-9242-09173F13E4C5 n11:271B3E96-363D-11E5-9242-09173F13E4C5 n11:271B3E93-363D-11E5-9242-09173F13E4C5 n11:271B3E94-363D-11E5-9242-09173F13E4C5
n3:synonym
Silvadene Silver sulphadiazine Silver sulfadiazine Flamazine Sulfadiazine silver salt Silver sulfadiazinate
n3:toxicity
Acute oral toxicity (LD50) in rat is 10001 mg/kg.
n3:synthesisReference
Charles L. Fox, Jr., Shanta M. Modak, Paul Fox, "Wound dressing comprising silver sulfadiazine incorporated in animal tissue and method of preparation." U.S. Patent US4599226, issued September, 1977.
n26:hasConcept
n27:M0019872
foaf:page
n7:silver-sulfadiazine.html n9:silversulf.htm
n3:IUPAC-Name
n8:271B3EAF-363D-11E5-9242-09173F13E4C5
n3:InChI
n8:271B3EB5-363D-11E5-9242-09173F13E4C5
n3:Molecular-Formula
n8:271B3EB4-363D-11E5-9242-09173F13E4C5
n3:Molecular-Weight
n8:271B3EB1-363D-11E5-9242-09173F13E4C5
n3:Monoisotopic-Weight
n8:271B3EB2-363D-11E5-9242-09173F13E4C5
n3:SMILES
n8:271B3EB3-363D-11E5-9242-09173F13E4C5
n3:Water-Solubility
n8:271B3EAD-363D-11E5-9242-09173F13E4C5
n3:logP
n8:271B3EAE-363D-11E5-9242-09173F13E4C5 n8:271B3EAB-363D-11E5-9242-09173F13E4C5
n3:logS
n8:271B3EAC-363D-11E5-9242-09173F13E4C5
n12:hasATCCode
n13:D06BA01
n3:H-Bond-Acceptor-Count
n8:271B3EBB-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Donor-Count
n8:271B3EBC-363D-11E5-9242-09173F13E4C5
n3:InChIKey
n8:271B3EB6-363D-11E5-9242-09173F13E4C5
n3:Polar-Surface-Area--PSA-
n8:271B3EB7-363D-11E5-9242-09173F13E4C5
n3:Polarizability
n8:271B3EB9-363D-11E5-9242-09173F13E4C5
n3:Refractivity
n8:271B3EB8-363D-11E5-9242-09173F13E4C5
n3:Rotatable-Bond-Count
n8:271B3EBA-363D-11E5-9242-09173F13E4C5
n3:absorption
Very limited penetration through the skin. Only when applied to very large area burns is absorption into the body generally an issue.
n3:affectedOrganism
Pseudomonas aeruginosa Yeast and other fungi Various gram-negative and gram-positive eubacteria Candida albicans and other yeasts Staphylococcus aureus
n3:casRegistryNumber
22199-08-2
n3:category
n3:containedIn
n22:271B3EA6-363D-11E5-9242-09173F13E4C5 n22:271B3E9C-363D-11E5-9242-09173F13E4C5 n22:271B3EA2-363D-11E5-9242-09173F13E4C5 n22:271B3EA0-363D-11E5-9242-09173F13E4C5 n22:271B3EA1-363D-11E5-9242-09173F13E4C5 n22:271B3E9E-363D-11E5-9242-09173F13E4C5 n22:271B3E9F-363D-11E5-9242-09173F13E4C5 n22:271B3E9D-363D-11E5-9242-09173F13E4C5 n22:271B3EA7-363D-11E5-9242-09173F13E4C5 n22:271B3EA8-363D-11E5-9242-09173F13E4C5 n22:271B3EA4-363D-11E5-9242-09173F13E4C5 n22:271B3EA5-363D-11E5-9242-09173F13E4C5 n22:271B3EA3-363D-11E5-9242-09173F13E4C5
n3:Bioavailability
n8:271B3EC1-363D-11E5-9242-09173F13E4C5
n3:Ghose-Filter
n8:271B3EC3-363D-11E5-9242-09173F13E4C5
n3:MDDR-Like-Rule
n8:271B3EC4-363D-11E5-9242-09173F13E4C5
n3:Melting-Point
n8:271B3EC5-363D-11E5-9242-09173F13E4C5
n3:Number-of-Rings
n8:271B3EC0-363D-11E5-9242-09173F13E4C5
n3:Physiological-Charge
n8:271B3EBF-363D-11E5-9242-09173F13E4C5
n3:Rule-of-Five
n8:271B3EC2-363D-11E5-9242-09173F13E4C5
n3:Traditional-IUPAC-Name
n8:271B3EB0-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-acidic-
n8:271B3EBD-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-basic-
n8:271B3EBE-363D-11E5-9242-09173F13E4C5